In Reply to Khalifa and Sargos
- 1 July 2021
- journal article
- editorial
- Published by Elsevier BV in Endocrine
- Vol. 110 (3), 917-918
- https://doi.org/10.1016/j.ijrobp.2021.01.057
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- In Regard to Marcq et alEndocrine, 2021
- Phase 1 Trial of Atezolizumab Plus Trimodal Therapy in Patients With Localized Muscle-Invasive Bladder CancerEndocrine, 2021
- The Link Between the Gut Microbiome and Response to Immune Checkpoint Inhibitors in Renal Cell CarcinomaEuropean Urology, 2020
- Microbiome transplantation and modulation of immune related adverse eventsEClinicalMedicine, 2019
- Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital ExperienceEuropean Urology, 2017
- Whole-Pelvis or Bladder-Only Chemoradiation for Lymph Node–Negative Invasive Bladder Cancer: Single-Institution ExperienceEndocrine, 2012
- Stage‐specific impact of pelvic lymph node dissection on survival in patients with non‐metastatic bladder cancer treated with radical cystectomyBJU International, 2011
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Stage Specific Lymph Node Metastasis Mapping in Radical Cystectomy SpecimensJournal of Urology, 2004
- Extended Radical Lymphadenectomy in Patients With Urothelial Bladder Cancer:: Results of a Prospective Multicenter StudyJournal of Urology, 2004